Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
BYSI logo BYSI
Upturn stock ratingUpturn stock rating
BYSI logo

BeyondSpring Inc (BYSI)

Upturn stock ratingUpturn stock rating
$1.87
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

09/15/2025: BYSI (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

1 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $1.25

1 Year Target Price $1.25

Analysts Price Target For last 52 week
$1.25 Target price
52w Low $0.98
Current$1.87
52w High $3.44

Analysis of Past Performance

Type Stock
Historic Profit 24.06%
Avg. Invested days 41
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 3.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 09/15/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 73.40M USD
Price to earnings Ratio -
1Y Target Price 1.25
Price to earnings Ratio -
1Y Target Price 1.25
Volume (30-day avg) 1
Beta 0.22
52 Weeks Range 0.98 - 3.44
Updated Date 09/15/2025
52 Weeks Range 0.98 - 3.44
Updated Date 09/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.2

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -20.74%
Return on Equity (TTM) -310.48%

Valuation

Trailing PE -
Forward PE 10.54
Enterprise Value 64337822
Price to Sales(TTM) 31.22
Enterprise Value 64337822
Price to Sales(TTM) 31.22
Enterprise Value to Revenue 26.53
Enterprise Value to EBITDA 0.05
Shares Outstanding 40332300
Shares Floating 30319015
Shares Outstanding 40332300
Shares Floating 30319015
Percent Insiders 15.26
Percent Institutions 14.6

ai summary icon Upturn AI SWOT

BeyondSpring Inc

stock logo

Company Overview

overview logo History and Background

BeyondSpring Inc. is a global biopharmaceutical company founded in 2010, focused on developing innovative cancer therapies. It has evolved from early-stage research to late-stage clinical development, with a primary focus on its lead asset, Plinabulin.

business area logo Core Business Areas

  • Oncology Drug Development: Focuses on the development and commercialization of Plinabulin and other oncology therapies to address unmet medical needs in various cancer types. The company's main drug Plinabulin is being studied in combination with other anti-cancer agents for a broad range of cancer indications.

leadership logo Leadership and Structure

The leadership team consists of key executives including the CEO, CFO, and Chief Medical Officer. The organizational structure is typical of a biopharmaceutical company, with departments for research and development, clinical operations, regulatory affairs, and commercialization.

Top Products and Market Share

overview logo Key Offerings

  • Plinabulin: Plinabulin is BeyondSpring's lead drug candidate. It is a selective vasculo-disrupting agent (VDA) and immune-enhancing agent being developed to prevent chemotherapy-induced neutropenia (CIN) and potentially treat various cancers. Competitors in CIN include Neulasta (Amgen) and Granix (Teva).

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is characterized by intense competition, high R&D costs, and stringent regulatory requirements. It involves the discovery, development, manufacturing, and commercialization of pharmaceutical drugs for various diseases. Significant unmet needs exist for novel cancer therapies, driving innovation and investment in this area.

Positioning

BeyondSpring is positioned as a late-stage biopharmaceutical company focused on oncology. Its competitive advantage lies in Plinabulin's novel mechanism of action and potential to address unmet needs in CIN and cancer treatment. However, its smaller size and limited resources pose challenges against larger, established competitors.

Total Addressable Market (TAM)

The TAM for CIN is estimated to be in the billions of dollars. The overall oncology market is significantly larger. BeyondSpring's position regarding TAM depends on the success of its clinical trials and regulatory approvals for Plinabulin in different indications.

Upturn SWOT Analysis

Strengths

  • Novel drug candidate (Plinabulin)
  • Targeting significant unmet medical needs
  • Late-stage clinical development
  • Experienced management team

Weaknesses

  • Limited financial resources
  • Dependence on Plinabulin success
  • Lack of established commercial infrastructure
  • History of regulatory challenges/denials

Opportunities

  • Potential regulatory approvals for Plinabulin
  • Expansion into new indications
  • Strategic partnerships or collaborations
  • Acquisition by a larger pharmaceutical company

Threats

  • Clinical trial failures
  • Regulatory setbacks
  • Competition from established players
  • Market access and reimbursement challenges
  • Patent expirations

Competitors and Market Share

competitor logo Key Competitors

  • AMGN
  • TEVA
  • SGEN

Competitive Landscape

BeyondSpring faces intense competition from established pharmaceutical companies with larger R&D budgets, commercial infrastructure, and market access. BeyondSpring's success depends on differentiating Plinabulin based on efficacy, safety, and convenience.

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been primarily driven by clinical development milestones and fundraising activities.

Future Projections: Future growth depends heavily on Plinabulin's regulatory approvals and commercial success. Analyst estimates vary based on the likelihood of approval and market penetration.

Recent Initiatives: Recent initiatives include pursuing regulatory approvals for Plinabulin in the U.S. and China, exploring strategic partnerships, and managing its cash position.

Summary

BeyondSpring is a biopharmaceutical company with a late-stage asset, Plinabulin, targeting unmet needs in oncology, particularly CIN. While the company has the potential for growth, its financial stability, regulatory hurdles, and competition from larger companies pose significant risks. Success hinges on Plinabulin's approval and commercialization and securing additional funding to support its operations. Recent regulatory setbacks and financial constraints require careful monitoring.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company filings
  • Analyst reports
  • Industry databases

Disclaimers:

This analysis is based on publicly available information and is not financial advice. Investors should conduct their own due diligence before making any investment decisions. Market share data is approximate and may vary based on source and methodology.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About BeyondSpring Inc

Exchange NASDAQ
Headquaters Florham Park, NJ, United States
IPO Launch date 2017-03-09
Co-Founder, Chairman & CEO Dr. Lan Huang Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 40
Full time employees 40

BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. It operates through two segments: Plinabulin pipeline and TPD platform. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy and radiation; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.